- 向PHARMAC提供$1.5亿（分两年）的资金，以确保在面对全球供应挑战时保持药品和医疗设备的供应
- 进一步投资（$3000万）用于接触追踪及其基础技术开发
- 支持开发全国免疫解决方案的全部资金，以便在新冠病毒疫苗出现时可以使用
- $3500万用于购买和安装用于向患者提供氧气的设备（可支持更多呼吸机和呼吸设备）
- 另外的$5,000万用于个人防护设备（PPE）
政府已采取措施确保所需药品充足，同时又在病毒接触追踪和其他疫情健康应对方面投入更多资金。
“在一段时间内，世界将继续承受全球疫情的持续影响。重要的是，我们必须对我们的卫生健康服务继续投资，并提高应对病毒的能力。”部长说。
“本届政府大大增加了对PHARMAC的投入来购买药品。仅在去年，我们就追加投资$2.2亿，并因疫情而一次增加$3500万。但是，由于全球疫情引起了供应问题，药品成本增加了。”
“例如，为了做好ICU患者的治疗做准备，PHARMAC确保增加了几种药物的库存，包括丙泊酚（propofol），芬太尼（fentanyl ）和去甲肾上腺素（noradrenaline）等。获得这些药物的费用比疫情前出约70％。”
“病毒的传播比以往任何时候都快，所以很明显，对供应链的破坏可能将持续，并且需要更多的投资。这就是为什么政府今年从新冠病毒响应和恢复基金中拨款$7400万用于PHARMAC，并在2021/22中又批准拨款$7600万。”
“这将意味着PHARMAC将有资金继续购买新西兰人所需的药品和医疗器械。”部长说。
政府还批准了更多相关的资金，以增强新西兰应对疫情持续威胁的能力，包括接触追踪，为疫苗接种做好技术准备，以及投入更多资金来应对持续增长的远程医疗服务。
“新西兰在应对疫情方面做得非常出色，我们现在拥有世界上最严格的边境保护措施，阻止病毒入境。同时，我们也一直在评估并改善我们的应对系统和流程。”
“我们将向全国接触追踪服务中心再投资$3000万，提高技术能力，并支持追踪应用程序的持续开发。”
追踪接触者是我们应对疫情的关键支柱之一。这项投资将进一步加强我们在一级预警下的联系追踪能力。
“还将投入$2300万开发国家免疫解决方案，以便在新冠病毒疫苗出现时，我们可以推出大规模疫苗接种计划。而之前的投资为$1500万。”
“我们需要立即开始工作，以取代目前的国家免疫登记记录，以应付疫苗接种活动的规模和复杂性。”
“我们还对医院的基础设施进行了更多投资，以支持呼吸机的使用；投入$3500万将用于购买更多氧气供应必要装备，以确保以正确的压力输送氧气。”
“所有这些投资都将进一步增强我们应对全球疫情的能力。新西兰应对疫情的水平一直是世界领先的，我们打算保持这种状态。”部长说。
注意：总投资额为$3.026亿，包括：
- $1.5亿用于通过PHARMAC购买药品和医疗器械
- $5000万用于个人防护装备
- $3500万的氧气供应（其中$2500万为资本金，$1000万为运营资金）
- $3000万用于全国密切接触者联系服务
- $1460万用于远程医疗服务
- $2300万用于开发国家免疫解决方案（$1400万的运营资金和$900万的资本）
（以上为简译，仅供参考，具体内容请见原文）
英文原文
Securing medicine supply and investing in COVID-19 capacity
- $150 million (over two years) for PHARMAC to secure the ongoing supply of medicines and medical devices in the face of global supply challenges
- Further investment ($30 million) in the National Close Contact Service and the technology that underpins its work
- Full funding for the development of the National Immunisation Solution so it is ready for when a COVID-19 vaccine is available
- $35 million to purchase and install equipment to supply oxygen to patients (to support the use of more ventilators and respiratory equipment)
- An additional $50 million for PPE supplies
The Government has moved to ensure New Zealanders continue to get access to the medicines they need, while at the same time investing more in contact tracing and other COVID-19 health responses.
“The world is going to be living with the ongoing impacts of the COVID-19 global pandemic for some time. It’s important we continue to invest in our health services and build our capacity to respond to the virus,” Health Minister Chris Hipkins said.
“This Government has significantly boosted funding for PHARMAC to purchase medicines. In the last year alone we have announced an extra $220 million investment, as well as a one-off boost of $35 million in response to COVID-19.
“However, the cost of medicines has increased due to supply issues caused by the global pandemic.
“For example, to prepare for a potential COVID-19 related increase in treatment of patients in ICU, PHARMAC secured additional stock of several medicines including propofol, fentanyl and noradrenaline. Securing these medicines cost approximately 70% more than would have been expected prior to the pandemic.
“With the virus now spreading faster than ever it’s clear that disruption to supply chains will continue and more investment is needed.
“That’s why the Government has approved $74 million more for PHARMAC this year, and $76 million in 2021/22, out of the Covid Response and Recovery Fund.
“This will mean PHARMAC can continue to purchase the medicines and medical devices New Zealanders need,” Chris Hipkins said.
Further health funding has also been approved to strengthen New Zealand’s capacity to respond to the ongoing threat from COVID-19, including through contact tracing, technology to support the roll-out of a future vaccine and more money to reflect the ongoing increase in demand for telehealth services.
“New Zealanders have done incredibly well to eliminate community spread of COVID-19 and we have some of the toughest border protections in the world to keep the virus at bay. But we can’t take anything for granted.
“We are constantly reviewing our response and improving our systems and processes.
“As part of that, we’re investing a further $30 million in the National Close Contact Service, including for surge capacity and information technology. It also supports the ongoing development of the COVID Tracer app.
“Contact tracing is one of the key pillars of our defence against COVID-19 and other infectious diseases. This investment will further strengthen our contact tracing capability at a national level.
“A further $23 million will be used to develop a National Immunisation Solution, so that when a COVID-19 vaccine is developed we are ready to roll out a mass vaccination programme. This builds on an earlier investment of $15 million.
“We can’t afford to wait for a vaccine to be available – we need to start work now to replace the current National Immunisation Register, which simply could not cope with the scale and complexity of a mass COVID-19 vaccination campaign.
“We’re also investing in more in our hospitals’ infrastructure to support the use of ventilators in the event of an outbreak. $35 million will be used to purchase more oxygen supplies and the necessary gear to ensure it is delivered at the right pressure.
“All these investments are designed to further build our ability to respond to the global pandemic now and into the future. New Zealand’s health response to COVID-19 has been world leading – we intend to keep it that way,” Chris Hipkins said.
NOTE: In total investments worth $302.6 million have been announced today:
- $150 million for medicines and medical devices through PHARMAC
- $50 million for PPE
- $35 million for oxygen supply ($25 million of which is capital, with $10 million operational funding)
- $30 million for the National Close Contact Service
- $14.6 million for telehealth services
- $23 million to develop the National Immunisation Solution ($14 million of operational funding and $9 million capital)
版权声明：
1、凡《新西兰信报网》转载的新闻、观点等，版权归原新闻信源所有，新闻内容和观点不代表本新闻机构立场。
2、未经本机构许可，其他任何机构、个人不得复制、摘录、转载或以其他任何形式使用《新西兰信报网》采访、编译和其他知识产权的任何内容，违者将追究法律责任。
3、如有任何问题，请联系nzmessenger@xtra.co.nz。
